Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,771 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.
Yu ML, Tai CM, Mo LR, Kuo HT, Huang CF, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Hung CH, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Chen CY, Kao JH, Lin HC, Chuang WL, Peng CY. Yu ML, et al. Among authors: chen ct, chen gy, chen cl, chen cy. Hepatol Int. 2024 Apr;18(2):461-475. doi: 10.1007/s12072-023-10609-7. Epub 2024 Jan 21. Hepatol Int. 2024. PMID: 38246899 Free PMC article.
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
Chen CY, Chuang WL, Qin A, Zhang WH, Zhu LY, Zhang GQ, Chen JJ, Lo CC, Zhou X, Mao X, Shang J, Kuo HT, Xie W, Chen CH, Lo GH, Jun DW, Dang S, Tsai CY, Wang TF, Lai HH, Tseng KC, Huang YW, Chen PJ. Chen CY, et al. Among authors: chen jj, chen ch, chen pj. JGH Open. 2022 Oct 10;6(11):782-791. doi: 10.1002/jgh3.12825. eCollection 2022 Nov. JGH Open. 2022. PMID: 36406648 Free PMC article.
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Liou JM, et al. Among authors: chen cc, chen py, chen cy, chen mj. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):228-241. doi: 10.1016/S2468-1253(22)00384-3. Epub 2022 Dec 19. Lancet Gastroenterol Hepatol. 2023. PMID: 36549320 Clinical Trial.
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Choi WM, et al. Among authors: chen ch, chen cy. J Hepatol. 2023 Mar;78(3):534-542. doi: 10.1016/j.jhep.2022.12.007. Epub 2022 Dec 23. J Hepatol. 2023. PMID: 36572349 Free article.
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.
Liu CH, Peng CY, Liu CJ, Chen CY, Lo CC, Tseng KC, Su PY, Kao WY, Tsai MC, Tung HD, Cheng HT, Lee FJ, Huang CS, Huang KJ, Shih YL, Yang SS, Wu JH, Lai HC, Fang YJ, Chen PY, Hwang JJ, Tseng CW, Su WW, Chang CC, Lee PL, Chen JJ, Chang CY, Hsieh TY, Chang CH, Huang YJ, Kao JH. Liu CH, et al. Among authors: chen jj, chen py, chen cy. Hepatol Int. 2023 Apr;17(2):291-302. doi: 10.1007/s12072-022-10475-9. Epub 2023 Jan 26. Hepatol Int. 2023. PMID: 36701081
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
Chang TS, Huang CF, Kuo HT, Lo CC, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Hung CH, Yu ML. Chang TS, et al. Among authors: chen ct, chen gy, chen cy. Hepatol Int. 2023 Jun;17(3):550-561. doi: 10.1007/s12072-023-10506-z. Epub 2023 Mar 27. Hepatol Int. 2023. PMID: 36973633 Free PMC article.
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ, Chen PY, Fang YJ, Bair MJ, Chen CC, Chen CC, Yang TH, Lee JY, Yu CC, Kuo CC, Chiu MC, Chou CK, Chen CY, Hu WH, Tsai MH, Hsu YC, Shun CT, Luo JC, Lin JT, El-Omar EM, Wu MS, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Chen MJ, et al. Among authors: chen cc, chen py, chen cy. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):623-634. doi: 10.1016/S2468-1253(23)00097-3. Epub 2023 May 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37178702 Clinical Trial.
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.
Cheng PN, Chen WJ, Hou CJ, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ. Cheng PN, et al. Among authors: chen wj, chen cy. Clin Mol Hepatol. 2024 Jan;30(1):16-36. doi: 10.3350/cmh.2023.0315. Epub 2023 Oct 4. Clin Mol Hepatol. 2024. PMID: 37793641 Free PMC article. Review.
7,771 results